Tecentriq – Page 2 – Medical News Asia

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

15 October 2018/0 Comments/in Medical News Asia, Gastrointestinal Cancer, Lung Cancer, Oncology, Immunotherapy, Targeted Therapies/by scienterrific

SUZHOU, China, Oct. 14, 2018 /PRNewswire/ — The combination therapy of novel programmed death 1 (PD-1) antibody IBI308 (sintilimab, Innovent Biologics) with biosimilar bevacizumab antibody IBI305 (Innovent Biologics) has received the investigational new drug (IND) application for clinical development approval by the National Medical Products Administration (NMPA, formerly known as CFDA) in China.

IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

11 October 2018/1 Comment/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy/by scienterrific

Atezolizumab (Tecentriq®, Roche/Genentech) plus standard chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer (SCLC) was associated with a significantly longer overall survival (OS) and progression-free survival (PFS) when compared with chemotherapy alone.

Frontline atezolizumab plus chemotherapy improves PFS in NSCLC

25 September 2018/0 Comments/in WCLC 2018, Lung Cancer, Oncology, Chemotherapy, Immunotherapy/by scienterrific

An interim analysis of the Phase III IMpower132 study showed that atezolizumab (Tecentriq®, Roche/Genentech) plus platinum-based chemotherapy (cisplatin or carboplatin) with pemetrexed improves the median progression-free survival (PFS) in treatment-naïve patients with non-squamous non-small cell lung cancer (NSCLC). The median PFS for atezolizumab plus pemetrexed and a platinum salt was 7.6 months vs 5.2 months with chemotherapy alone (HR=0.60, 95% CI: 0.49-0.72; p<0.0001).

Plasma TMB predicts response to atezolizumab in NSCLC patients

31 August 2018/0 Comments/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Pathology, Translational Research/by scienterrific

A high tumour mutational burden in the plasma (bTMB) is a clinically actionable biomarker for atezolizumab (Tencentriq®, Roche) treatment in patients who failed 1st-line platinum-based therapy for advanced non-small cell lung cancer (NSCLC).

Pembrolizumab and atezolizumab USPIs updated by FDA

21 August 2018/1 Comment/in US FDA Onc\Haem Approvals, Genitourinary Cancer, Oncology, Immunotherapy/by scienterrific

On the 16th of August, 2018, the FDA updated the prescribing information for pembrolizumab (Keytruda®, Merck) and atezolizumab (Tecentriq®, Roche/Genentech) and added the requirement for the use of an FDA-approved companion diagnostic test (CDx) to determine PD-L1 levels in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

25 June 2018/5 Comments/in ASCO 2018 Annual Meeting, Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies/by Anne John Michael

Non-small cell lung cancer (NSCLC): a key feature of the American Society of Clinical Oncology (ASCO) 2018 annual meeting. This year, encouraging results with single-agent immunotherapy (I-O) and combinations of I-O with chemotherapy (CTx), including the CheckMate 227 with nivolumab (NIVO), IMpower131 and IMpower150 studies with atezolizumab (ATEZO), and KEYNOTE-042 and KEYNOTE-407 studies with pembrolizumab (PEMBRO). Furthermore, important Asian data on treatments for epidermal growth-factor recptor (EGFR) mutation-positive (mu+) NSCLC (ARCHER 1050, NEJ009, NEJ026, and JO25567).

FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma

19 June 2018/1 Comment/in US FDA Onc\Haem Approvals, Genitourinary Cancer, Oncology, Immunotherapy, Translational Research/by scienterrific

On June 19, the FDA limited the use of atezolizumab and pembrolizumab for the treatment of locally advanced or metastatic urothelial cancer patients ineligible for cisplatin-containing therapy.

ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

10 June 2018/5 Comments/in ASCO 2018 Annual Meeting, Conferences, Gastrointestinal Cancer, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies, Translational Research/by Anne John Michael

This year’s American Society of Clinical Oncology (ASCO) annual meeting includes two Phase III studies in the second-line treatment of the disease. Moreover, data with several immune-checkpoint inhibitors were presented, including the KEYNOTE-224 with pembrolizumab. Welcome to the summary of the ASCO 2018 HCC track.

FDA safety alert: use of immunotherapy in metastatic urothelial cancer with low PD-L1 expression

18 May 2018/2 Comments/in US FDA Onc\Haem Approvals, Uncategorised/by Stijn van den Borne, MSc

On May 18, the United States (US) Food and Drug Administration (FDA) issued an alert about the decreased survival in studies with pembrolizumab (Keytruda®) and atezolizumab (Tecentriq®) as single agent first-line therapy for patients with metastatic urothelial cancer (mUCC) and low expression of the programmed death ligand 1 (PD-L1) protein.

Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

26 March 2018/5 Comments/in Lung Cancer, Oncology, Immunotherapy, Guidelines/by Stijn van den Borne, MSc

The expansion of therapeutic options with immunotherapies will reflect a dramatic change in the guidelines for lung cancer, where immunotherapies mostly compete with the use of chemotherapeutic agents. A brief communication on immunotherapies for NSCLC.

Tag Archive for: Tecentriq